Vertex Pharmaceuticals

American pharmaceutical company

VRTX Nasdaq ISIN US92532F1003 SEC CIK 875320
Follow Vertex Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $3.4B +11.8% vs same quarter last year
Net income $653.6M −39.6% vs same quarter last year
EPS, diluted $2.56 −39% vs same quarter last year
Operating cash flow $643.1M −48.2% vs same quarter last year
Revenue by quarter
$2.9B
$2.8B
$3B
$3.1B
$3.2B
$3B
$3.3B
$3.4B
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$5B$0$5B$10B$15BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$12B$4B
FY24$11B−$535.6M
FY23$9.9B$3.6B
FY22$8.9B$3.3B
FY21$7.6B$2.3B
FY20$6.2B$2.7B
FY19$4.2B$1.2B
FY18$3B$2.1B
FY17$2.5B$263.5M
FY16$1.7B−$112.1M
FY15$1B−$556.3M
FY14$580.4M−$738.6M
FY13$1.2B−$445M
FY12$1.5B−$107M
FY11$1.4B$29.6M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−200%−100%0%100%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2586.2%34.8%32.9%
FY2486.1%−2.1%−4.9%
FY2387.2%38.8%36.7%
FY2287.9%48.2%37.2%
FY2188.1%36.7%30.9%
FY2088.1%46%43.7%
FY1986.8%28.8%28.3%
FY1886.6%20.8%68.8%
FY1788.9%5%10.6%
FY1687.6%0.6%−6.6%
FY1588.7%−45.2%−53.9%
FY1493.2%−119.3%−127.2%
FY1392.7%−50.3%−36.7%
FY1284.5%3.1%−7%
FY1195.5%8.1%2.1%
Free cash flowOperating cash flow minus capital expenditure
−$2B$0$2B$4BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25$3.2B
FY24−$790.3M
FY23$3.3B
FY22$3.9B
FY21$2.4B
FY20$3B
FY19$1.5B
FY18$1.2B
FY17$745.5M
FY16$179.5M
FY15−$410.7M
FY14−$624.3M
FY13−$112.1M
FY12$196.7M
FY11$109.1M
Returned to shareholdersDividends paid and shares bought back
$0$1B$2B$3BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25$2B
FY24$1.2B
FY23$427.6M
FY22$0
FY21$1.4B
FY20$539.1M
FY19$186M
FY18$350M
FY17$0
FY16$0
FY15-
FY14-
FY13-
FY12-
FY11-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Vertex Pharmaceuticals
  • Healthcare median
−150%−100%−50%0%50%100%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearVertex PharmaceuticalsHealthcare median
FY2532.9%−30.6%
FY24−4.9%−47%
FY2336.7%−58%
FY2237.2%−80.4%
FY2130.9%−71.9%
FY2043.7%−62.2%
FY1928.3%−46.3%
FY1868.8%−49.6%
FY1710.6%−45.9%
FY16−6.6%−36%
FY15−53.9%−38.4%
FY14−127.2%−35.5%
FY13−36.7%−37.1%
FY12−7%−29.1%
FY112.1%−27.9%